Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
172
resultados
Última actualización
10/10/2025 [06:48:00]
Resumen de: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Resumen de: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Resumen de: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Resumen de: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Resumen de: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
Nº publicación: EP4610657A1 03/09/2025
Solicitante:
UNIV KEIO [JP]
Keio University
Resumen de: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
BOPI
Sede Electrónica
